BRAF and MEK inhibitors (BRAFi and MEKi) are now approved for the treatment of BRAFV600E/K melanoma [9,10] and colorectal cancer [11]; the MEKi, Selumetinib, is approved for the treatment of paediatric neurofibromatosis, a RASopathy driven by deregulated RAS activation [12] and ERK1/2 inhibitors are in development [13]. Here, BRAF is linked to colorectal cancer.